Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1991-10-7
pubmed:abstractText
Strategies have been developed to rid bone marrow of microscopic tumor prior to infusion in the autologous bone marrow transplant setting. We have previously demonstrated that recombinant human interleukin-2 (IL-2) is effective in such an experimental setting involving a methylcholanthrene-induced fibrosarcoma in mice. The purpose of the current work was to determine whether IL-2 treatment after, or before and after bone marrow transplantation would influence bone marrow engraftment or degree of hematologic reconstitution. We found that stem cell number (CFU-S) and posttransplant marrow cellularity were comparable in IL-2-treated or saline-treated mice. Furthermore, after engraftment, marrow stem cell and myeloid progenitor cell numbers were greater in the IL-2 treatment group. These results suggest that IL-2 will prove to be safe when administered in bone marrow transplant patients.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1056-5477
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
185-8
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
The effects of interleukin-2 on bone marrow engraftment in a murine model.
pubmed:affiliation
Department of Medicine, University of Wisconsin-Madison 53706.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't